New Hepatitis C Regimen Achieves SVR in 6 Weeks
An experimental hepatitis C (HCV) drug, when combined with sofosbuvir, effectively eliminated all signs of the HCV within 6 weeks, according to a news release from Achillion Pharmaceuticals.
The ongoing Phase 2 study examined the safety, tolerability, and efficacy of the combination of 50 mg of ACH-3102 and 400 mg of sofosbuvir in treating naïve genotype 1 HCV-infected patients.
____________________________________________________________________________________________________________________________________________________________________
RELATED CONTENT
CDC: 1 Million "High Priority" HCV Cases in the US
New Hepatitis C Treatment Options Emerging
____________________________________________________________________________________________________________________________________________________________________
Twelve weeks after the completion of therapy, 100% (12/12) of the participants in an 8-week treatment arm achieved sustained virologic response (SVR12). Following this, the researchers initiated a 6-week treatment arm. After 12 weeks, 100% (12/12) of the participants in the 6-week arm of study had achieved SVR12, and 100% of those in the 8-week treatment arm had achieved SVR24.
“The combination of ACH-3102 and sofosbuvir was well-tolerated with no serious adverse events, no discontinuations due to adverse events, and no clinically significant laboratory or ECG abnormalities,” they wrote.
"The achievement of 100% SVR12 after six weeks of treatment with a dual NS5A-nucleotide regimen, even in patients with high baseline viral load who would otherwise require extended duration treatments, supports our belief that ACH-3102 can unleash the potential of this combination to drive down treatment duration," they concluded.
-Michelle Canales
Reference:
Achillion. Achillion achieves 100% SVR12 Phase 2 Trial evaluating 6-week combination treatment with ACH-3102 [press release]. February 9, 2015. http://ir.achillion.com/releasedetail.cfm?releaseid=895306. Accessed February 9, 2015.